GlycoNet is advancing research, innovation, and training in glycomics to improve the quality of life of Canadians.

GlycoNet is a one-stop global destination focused on developing new carbohydrate-based drugs, vaccines and diagnostics, in collaboration with academic and industry organizations to address areas of unmet need through applied glycomics research. This national platform supports translational research, protection of intellectual property, novel drug development, company formation and training of a new generation of glyco-scientists and entrepreneurs. The network includes over 170 researchers across Canada who focus on cancer, chronic diseases, infectious diseases, and neurodegenerative diseases.

GlycoNet is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.

GlycoNet “punches above its weight” in glycomics innovation.
(Institute of Health Economics Report, 2021)

Network Investigators
Trained HQP
Funded Projects
Network Partners

Latest News

GlycoNet researchers develop new chemical biological tools to monitor Parkinson’s disease

Researchers are a step closer to understanding how Parkinson’s disease develops and progresses.

GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions

Glycomics is an integral part of ABOzymes’ life-saving research and technology development.

Engagement and collaboration in action at the 2022 Canadian Glycomics Symposium

Read some highlights from the 2022 Canadian Glycomics Symposium.

Network Members

Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147

Subscribe to GlycoNet’s Newsletter


Scroll to Top